Cargando…
Technical and clinical validation of the Allergen BioCube(®) for timothy grass
INTRODUCTION: Field studies for allergic rhinitis (AR) commonly have inconsistent allergen concentrations and subject exposure patterns due to varying environmental conditions and subject behaviors. A technical and clinical validation study was conducted for the Allergen BioCube(®) using timothy gra...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322160/ https://www.ncbi.nlm.nih.gov/pubmed/28250927 http://dx.doi.org/10.1002/iid3.143 |
_version_ | 1782509798137266176 |
---|---|
author | Angjeli, Endri Gomes, Paul Lane, Keith J. Stein, Linda Abelson, Mark B. |
author_facet | Angjeli, Endri Gomes, Paul Lane, Keith J. Stein, Linda Abelson, Mark B. |
author_sort | Angjeli, Endri |
collection | PubMed |
description | INTRODUCTION: Field studies for allergic rhinitis (AR) commonly have inconsistent allergen concentrations and subject exposure patterns due to varying environmental conditions and subject behaviors. A technical and clinical validation study was conducted for the Allergen BioCube(®) using timothy grass to confirm uniform allergen concentration and clinically relevant subject symptom responses. METHODS: Allergen concentrations were verified by laser particle counts. Subjects (N = 14) with positive skin test reactions and no symptoms at screening received four 3‐h timothy grass exposures in the BioCube over consecutive days. Subjects evaluated nasal itching, sneezing, rhinorrhea, and nasal congestion while in the BioCube; Total Nasal Symptom Score (TNSS) was computed. Peak Nasal Inspiratory Flow (PNIF), Peak Expiratory Flow Rate (PEFR), sIgE blood tests, and Nasal Inflammation Score (NIS) were assessed. A correlation analysis was conducted for mean sIgE, skin test, and TNSS. RESULTS: Uniform timothy grass concentrations were achieved in the BioCube, both spatially and temporally, at all subject positions. Mean TNSS increased substantially from pre‐exposure levels (0.36 ± 0.74 to 1.86 ± 2.14) to maximums of 7.07 ± 2.76 at 1.5 h and 6.71 ± 2.70 at 3 h BioCube exposure. Twelve (86%) subjects had TNSS increases ≥6 units. PNIF decreased 12–24% from baseline at 3‐h BioCube exposure. NIS increased (baseline = 0) to 3.7 (maximum score = 4). A low/moderate correlation (r = 0.485) occurred between mean sIgE blood levels and mean skin tests; neither sIgE or skin tests correlated with mean TNSS. However, subjects with high skin test scores or positive blood IgE tended to also have higher TNSS. CONCLUSIONS: The Allergen BioCube achieved technical and clinical validation for uniform timothy grass concentration and clinically meaningful AR sign and symptom responses. The Allergen BioCube can be used to assess the efficacy of therapies for reduction of AR signs and symptoms resulting from grass exposure. |
format | Online Article Text |
id | pubmed-5322160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53221602017-03-01 Technical and clinical validation of the Allergen BioCube(®) for timothy grass Angjeli, Endri Gomes, Paul Lane, Keith J. Stein, Linda Abelson, Mark B. Immun Inflamm Dis Original Research INTRODUCTION: Field studies for allergic rhinitis (AR) commonly have inconsistent allergen concentrations and subject exposure patterns due to varying environmental conditions and subject behaviors. A technical and clinical validation study was conducted for the Allergen BioCube(®) using timothy grass to confirm uniform allergen concentration and clinically relevant subject symptom responses. METHODS: Allergen concentrations were verified by laser particle counts. Subjects (N = 14) with positive skin test reactions and no symptoms at screening received four 3‐h timothy grass exposures in the BioCube over consecutive days. Subjects evaluated nasal itching, sneezing, rhinorrhea, and nasal congestion while in the BioCube; Total Nasal Symptom Score (TNSS) was computed. Peak Nasal Inspiratory Flow (PNIF), Peak Expiratory Flow Rate (PEFR), sIgE blood tests, and Nasal Inflammation Score (NIS) were assessed. A correlation analysis was conducted for mean sIgE, skin test, and TNSS. RESULTS: Uniform timothy grass concentrations were achieved in the BioCube, both spatially and temporally, at all subject positions. Mean TNSS increased substantially from pre‐exposure levels (0.36 ± 0.74 to 1.86 ± 2.14) to maximums of 7.07 ± 2.76 at 1.5 h and 6.71 ± 2.70 at 3 h BioCube exposure. Twelve (86%) subjects had TNSS increases ≥6 units. PNIF decreased 12–24% from baseline at 3‐h BioCube exposure. NIS increased (baseline = 0) to 3.7 (maximum score = 4). A low/moderate correlation (r = 0.485) occurred between mean sIgE blood levels and mean skin tests; neither sIgE or skin tests correlated with mean TNSS. However, subjects with high skin test scores or positive blood IgE tended to also have higher TNSS. CONCLUSIONS: The Allergen BioCube achieved technical and clinical validation for uniform timothy grass concentration and clinically meaningful AR sign and symptom responses. The Allergen BioCube can be used to assess the efficacy of therapies for reduction of AR signs and symptoms resulting from grass exposure. John Wiley and Sons Inc. 2017-02-02 /pmc/articles/PMC5322160/ /pubmed/28250927 http://dx.doi.org/10.1002/iid3.143 Text en © 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Angjeli, Endri Gomes, Paul Lane, Keith J. Stein, Linda Abelson, Mark B. Technical and clinical validation of the Allergen BioCube(®) for timothy grass |
title | Technical and clinical validation of the Allergen BioCube(®) for timothy grass |
title_full | Technical and clinical validation of the Allergen BioCube(®) for timothy grass |
title_fullStr | Technical and clinical validation of the Allergen BioCube(®) for timothy grass |
title_full_unstemmed | Technical and clinical validation of the Allergen BioCube(®) for timothy grass |
title_short | Technical and clinical validation of the Allergen BioCube(®) for timothy grass |
title_sort | technical and clinical validation of the allergen biocube(®) for timothy grass |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322160/ https://www.ncbi.nlm.nih.gov/pubmed/28250927 http://dx.doi.org/10.1002/iid3.143 |
work_keys_str_mv | AT angjeliendri technicalandclinicalvalidationoftheallergenbiocubefortimothygrass AT gomespaul technicalandclinicalvalidationoftheallergenbiocubefortimothygrass AT lanekeithj technicalandclinicalvalidationoftheallergenbiocubefortimothygrass AT steinlinda technicalandclinicalvalidationoftheallergenbiocubefortimothygrass AT abelsonmarkb technicalandclinicalvalidationoftheallergenbiocubefortimothygrass |